Page last updated: 2024-11-06

floxuridine and ER-Negative PR-Negative HER2-Negative Breast Cancer

floxuridine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, N1
Liang, X1
Gao, C1
Chen, M1
Zhou, Y1
Krueger, CJ1
Bao, G1
Gong, Z1
Dai, Z1

Other Studies

1 other study available for floxuridine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Loading Lovastatin into Camptothecin-Floxuridine Conjugate Nanocapsules for Enhancing Anti-metastatic Efficacy of Cocktail Chemotherapy on Triple-negative Breast Cancer.
    ACS applied materials & interfaces, 2018, Sep-05, Volume: 10, Issue:35

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Floxuridine; Humans; Lovastatin; Mic

2018